Chemoradiation-induced alteration of programmed death-ligand 1 (PD-L1) and CD8+ tumor-infiltrating lymphocytes identified the patients with poor prognosis in rectal cancer: a matched comparison analysis
IJROBP Journal SA-CME activity for December 1, 2017 (Volume 99, Issue 5) examines immunotherapy mediated through blocking of checkpoint inhibitors that has an increasing and promising role in the management of malignant disease. Radiotherapy appears to have significant interactions with this form of immunotherapy.
Please visit www.redjournal.org/article/S0360-3016(17)33554-X/fulltext to read the related journal article online.
This activity is available from November 15, 2017, through 11:59 p.m. Eastern time on November 14, 2019.
This program is designed to meet the interest of radiation oncologists, radiation oncology residents as well as pathologists and scientists interested in GI, rectal cancer and/or immunotherapy of GI cancer.
Upon completion of this activity, participants should be able to:
- Cite evidence regarding induced changes in the expression levels of PD-L1 and CD8+ tumor-infiltrating lymphocytes (TILs) around rectal adenocarcinomas following neoadjuvant chemoradiotherapy.
- Relate these changes to the prognosis of these tumors.
Hong-Gyun Wu, MD, PhD has no financial relationships with a commercial interest.
Ross A Abrams, MD, FASTRO has no financial relationships with a commercial interest.
The person(s) above served as the developer(s) of this activity. Additionally, the Journal CME Task Force and CME/MOC Committee had control over the content of this activity.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
- 1.00 SA-CME
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing medical education for physicians.
The American Society for Radiation Oncology (ASTRO) designates this Journal-based CME activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity meets the American Board of Radiology's criteria for a self-assessment activity in the ABR's Maintenance of Certification program. Participation in this course in combination with the successful completion of the corresponding assessment and course evaluation adheres to the guidelines established by the ABR for 1.00 self-assessment credits.
- 1.00 Certificate of AttendanceThis activity was designated for 1.00 AMA PRA Category 1 Credit™.
ASTRO members must log in to the ASTRO website to view and receive the discounted member rate.
- Nonmember: $30
- Member: $25
No refunds, extensions, or substitutions will be made for those participants who, for any reason, have not completed the course by the end of the qualification date. The qualification date for each course is listed in the course catalog on the ASTRO website under availability.
Participants using ASTRO's online courses to satisfy the requirement of a Maintenance of Certification (MOC) program should verify the number, type and availability dates of any course before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased courses that do not align with their MOC requirement.
The course and its materials will only be available on the ASTRO website for that 3 year period regardless of purchase date. At the expiration of the qualification, participants will no longer have access to the course or its materials. ASTRO reserves the right to remove a course before the end of its qualification period.
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.